Oral glucocerebrosidase: Phase IIa started

Protalix began an open-label, dose-escalation, Israeli Phase IIa trial to evaluate 50, 100, 200 and 400 units of oral PRX-112 in 10 treatment-naive adult patients with Gaucher’s disease. Patients will receive PRX-112 once daily for 5 days at each dose, with a 2-day washout period between doses. ...